Cathepsin D inhibitors as potential therapeutics for breast cancer treatment: Molecular docking and bioevaluation against triple-negative and triple-positive breast cancers.

Autor: Anantaraju HS; Computer-Aided Drug Design Laboratory, Department of Pharmacy, Birla Institute of Technology & Science- Pilani, Hyderabad Campus, Shameerpet, R.R. District, Hyderabad, 500078, Telangana, India., Battu MB; Computer-Aided Drug Design Laboratory, Department of Pharmacy, Birla Institute of Technology & Science- Pilani, Hyderabad Campus, Shameerpet, R.R. District, Hyderabad, 500078, Telangana, India., Viswanadha S; Incozen Therapeutics (P)Ltd, Shameerpet, R.R. District, Hyderabad, 500078, Telangana, India., Sriram D; Computer-Aided Drug Design Laboratory, Department of Pharmacy, Birla Institute of Technology & Science- Pilani, Hyderabad Campus, Shameerpet, R.R. District, Hyderabad, 500078, Telangana, India.; Yogee'S Bioinnovations Private Limited, Room No. 5, Technology Business Incubator, Birla Institute of Technology & Science- Pilani, Hyderabad Campus, Shameerpet, Hyderabad, 500078, Telangana, India., Yogeeswari P; Computer-Aided Drug Design Laboratory, Department of Pharmacy, Birla Institute of Technology & Science- Pilani, Hyderabad Campus, Shameerpet, R.R. District, Hyderabad, 500078, Telangana, India. pyogee@hyderabad.bits-pilani.ac.in.; Yogee'S Bioinnovations Private Limited, Room No. 5, Technology Business Incubator, Birla Institute of Technology & Science- Pilani, Hyderabad Campus, Shameerpet, Hyderabad, 500078, Telangana, India. pyogee@hyderabad.bits-pilani.ac.in.
Jazyk: angličtina
Zdroj: Molecular diversity [Mol Divers] 2016 May; Vol. 20 (2), pp. 521-35. Date of Electronic Publication: 2015 Nov 13.
DOI: 10.1007/s11030-015-9645-8
Abstrakt: The main aim of this study was to discover small molecule inhibitors against Cathepsin D (CatD) (EC.3.4.23.5), a clinically proven prognostic marker for breast cancer, and to explore the mechanisms by which CatD could be a useful therapeutic target for triple-positive and triple-negative breast cancers (TPBC & TNBC). The crystal structure of CatD at 2.5 Å resolution (PDB: 1LYB), which was complexed with Pepstatin A, was selected for computer-aided molecular modeling. The methods used in our study were pharmacophore modeling and molecular docking. Virtual screening was performed to identify small molecules from an in-house database and a large commercial chemical library. Cytotoxicity studies were performed on human normal cell line HEK293T and growth inhibition studies on breast adenocarcinoma cell lines, namely MCF-7, MDA-MB-231, SK-BR-3, and MDA-MB-468. Furthermore, RT-PCR analysis, in vitro enzyme assay, and cell cycle analysis ascertained the validity of the selected molecules. A set of 28 molecules was subjected to an in vitro fluorescence-based inhibitory activity assay, and among them six molecules exhibited >50 % inhibition at 25μM. These molecules also exhibited good growth inhibition against TPBC and TNBC cancer types. Among them, molecules 1 and 17 showed single-digit micromolar GI50 values against MCF-7 and MDA-MB-231 cell lines.
Databáze: MEDLINE